Correlation of maternal serum glycosylated fibronectin in pre-eclampsia
European Journal of Molecular & Clinical Medicine,
2023, Volume 10, Issue 1, Pages 3427-3434
AbstractTo assess the correlation of maternal serum glycosylated fibronectin level in preeclamptic pregnant women with severity of pre-eclampsia.
Methods: An 18-month prospective study was conducted at the Rajarajeshwari Medical College and Hospital (RRMCH), Bengaluru, in the department of obstetrics and gynaecology (Jan 2021 – May 2022). Twenty-five preeclamptic pregnant women ≥20 weeks gestation made up the anticipated sample size. The LumellaTM PE test gadget was used to perform the maternal serum GlyFN test using the GlyFN POC device (from DiabetOmics, Inc.).
Results: There was statistically significant difference in severe pre-eclampsia between <=350 and >350 serum fibronectin values (P value <0.05). There were 93.75% (15 out of 16) severe pre-eclampsia cases in >350 serum fibronectin group where it was only 6.25% in <=350 group.
Conclusion: GlyFn POC test is a promising biochemical marker for severity of preeclampsia, and may be a useful adjunctive tool for rapid and accurate triage and intervention.
- Article View: 10
- PDF Download: 11